



Recent advances in recombinant protein-based malaria vaccines



Simon J. Draper ^{a,*}, Evelina Angov ^b, Toshihiro Horii ^c, Louis H. Miller ^d,
Prakash Srinivasan ^d, Michael Theisen ^{e,f}, Sumi Biswas ^a

^a The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK

^b Walter Reed Army Institute of Research, U. S. Military Malaria Research Program, Malaria Vaccine Branch, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA

^c Department of Molecular Protozoology, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 561-873, Japan

^d Malaria Cell Biology Section, Laboratory of Malaria and Vector Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA

^e Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark

^f Centre for Medical Parasitology at Department of International Health, Immunology, and Microbiology and Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

ARTICLE INFO

Article history:

Available online 11 October 2015

Keywords:

Malaria
Recombinant protein
Vaccine
Adjuvant
Plasmodium falciparum
Antibody

ABSTRACT

Plasmodium parasites are the causative agent of human malaria, and the development of a highly effective vaccine against infection, disease and transmission remains a key priority. It is widely established that multiple stages of the parasite's complex lifecycle within the human host and mosquito vector are susceptible to vaccine-induced antibodies. The mainstay approach to antibody induction by subunit vaccination has been the delivery of protein antigen formulated in adjuvant. Extensive efforts have been made in this endeavor with respect to malaria vaccine development, especially with regard to target antigen discovery, protein expression platforms, adjuvant testing, and development of soluble and virus-like particle (VLP) delivery platforms. The breadth of approaches to protein-based vaccines is continuing to expand as innovative new concepts in next-generation subunit design are explored, with the prospects for the development of a highly effective multi-component/multi-stage/multi-antigen formulation seeming ever more likely. This review will focus on recent progress in protein vaccine design, development and/or clinical testing for a number of leading malaria antigens from the sporozoite-, merozoite- and sexual-stages of the parasite's lifecycle—including PfCetTOS, PfMSP1, PfAMA1, PfRH5, PfSER45, PfGLURP, PfMSP3, Pfs48/45 and Pfs25. Future prospects and challenges for the development, production, human delivery and assessment of protein-based malaria vaccines are discussed.

© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Multiple stages of the *Plasmodium* parasite's lifecycle are susceptible to antibodies, including the liver-invasive sporozoite; the red blood cell (RBC)-invading merozoite; parasite stages within the infected erythrocyte (iRBC) which display antigen at the cell surface; as well as the sexual-stage forms present in both the human host and mosquito vector. This susceptibility has led to myriad efforts to develop subunit vaccines that can induce functional antibodies capable of preventing malaria infection, disease or transmission [1].

All subunit vaccines in their most basic form require delivery of antigen(s) believed to be targets of protective immunity, coupled with an immuno-stimulant or 'adjuvant' selected in the belief that this will lead to the induction of a strong and durable immune response of the appropriate type. Even these most basic of tenets have proved challenging in the context of antibody-inducing subunit vaccines for malaria, but much progress has been made.

The classical approach to antibody induction by subunit vaccination has been the delivery of protein antigen formulated in adjuvant, with notable success in humans including examples such as hepatitis B virus surface antigen (HBsAg) and bacterial toxoids (tetanus and diphtheria). In the case of malaria, the production of conformational recombinant proteins using heterologous expression platforms can prove challenging, especially when using bacterial-based systems [2]. However, numerous protein vaccine

* Corresponding author. Tel.: +44 1865 617624; fax: +44 1865 617608.

E-mail address: simon.draper@ndm.ox.ac.uk (S.J. Draper).

Table 1

Progress in the clinical development and testing of malaria vaccine candidates comprising recombinant protein/peptide/VLP and adjuvant.

	References
Recombinant malaria antigens progressed to clinical testing PfCSP; PfTRAP; PfCeITOS; PFAMA1; PfLSA1; PfLSA3; PfMSP1; PfMSP2; PfMSP3; PfGLURP; PfRESA; Pf27A; Pf1.1; PfEBA175; PfSERAS5; Pf230; Pf25; PvCSP; Pv25; [PfRH5; VAR2CSA; Pf48/45; PvDBP].	[173–178] Clinicaltrials.gov NCT00312702; NCT00509158; NCT01949909; NCT01605786
Heterologous expression systems used for cGMP manufacture <i>E. coli</i> ; <i>S. cerevisiae</i> ; <i>P. pastoris</i> ; <i>L. lactis</i> ; <i>N. benthamiana</i> ; <i>Pseudomonas fluorescens</i> ; <i>Drosophila</i> S2 cells.	[179]
Recombinant antigen delivery platforms tested in clinical trials Soluble protein; LSP; fusion protein; HBsAg VLP; EPA conjugate; Alfalfa mosaic virus coat protein VLP; virosome.	[180]
Protein adjuvants tested in clinical trials Adjuphos (aluminum phosphate); Alhydrogel (aluminum hydroxide/alum); Alhydrogel + CPG7909; AS01B; AS02A; Montanide ISA720; Montanide ISA51; GLA-SE.	[61,176]

Antigens, heterologous expression platforms, delivery platforms and adjuvants are listed. Protein-based antigens reported to be in clinical development but not yet in Phase I clinical testing are shown in square parentheses. Exemplar references are only included when information is not provided elsewhere in this review. LSA = liver-stage antigen; RESA = ring-infected erythrocyte surface antigen; EBA-175 = erythrocyte-binding antigen-175 kDa.

candidates have now been successfully produced to current Good Manufacturing Practice (cGMP) standard (using amongst others *Escherichia coli*, *Saccharomyces cerevisiae* and *Pichia pastoris*), and progressed to Phase I/II clinical testing (Table 1). Clinical progression also requires access to adjuvants which are safe and display acceptable reactogenicity profiles [3], but in turn are capable of eliciting antibody responses of sufficient magnitude to prevent rapidly invading or developing parasites. Our incomplete understanding of protective immune effector mechanisms *in vivo* in humans also continues to hamper vaccine development and prioritization [4]. Whether antibodies function through cell-independent neutralization type mechanisms or via Fc-mediated immune cell interactions is often unclear, as is the potential contribution of CD4⁺ T helper cell responses to B cell induction and memory maintenance, and IgG affinity maturation and subtype polarization. How adjuvant selection and antigen delivery can skew these parameters in humans is still poorly understood. With regard to antigen target selection, the malaria parasite genome possesses over 5000 genes, with complex expression patterns throughout all stages of the lifecycle [5]. The historical absence of biological information on the vast majority of gene products has meant that subunit vaccine development has traditionally focused on a relatively limited number of well-studied candidates.

Despite these great challenges, huge progress has been made with recombinant protein malaria subunits. Numerous antigens and adjuvants have now been tested in Phase I/II clinical trials yielding important and informative clinical data (Table 1). A variety of expression platforms have been used to produce soluble proteins, fusion antigens, long synthetic peptides (LSP), conjugates and antigen arrayed on virus-like particles (VLPs). Indeed, the leading anti-sporozoite subunit vaccine, RTS,S/AS01B, based on a recombinant VLP of HBsAg displaying repeats from the *P. falciparum* circumsporozoite protein (PfCSP), has shown moderate level efficacy of modest duration in Phase II/III clinical trials [6–8] and is progressing toward licensure. The breadth of approaches to protein vaccine design is now continuing to expand as innovative new concepts in next-generation subunit design and antigen discovery [see Doolan *et al.* in this review series] are explored, with the prospects for the development of a highly effective multi-component/multi-stage/multi-antigen formulation seeming ever more likely.

This review will focus on recent progress in protein vaccine design, development and/or clinical testing for a number of leading malaria antigens from the sporozoite-, merozoite- and sexual-stages of the parasite's lifecycle. Progress with PfCSP-based vaccines, especially RTS,S, has been reviewed in detail elsewhere [9,10] and in this Special Issue [Kaslow *et al.*], and the development of protein vaccines against the *P. vivax* Duffy-binding protein (PvDBP) are also covered in another article in this review series

[Chitnis *et al.*]. Future prospects and challenges for this field will be summarized.

2. Antigen candidates

2.1. PfCeITOS

Significant efforts are currently focused on identifying promising antigenic targets expressed on sporozoites and in early liver-stage development with the intent to combine and synergize immune responses against these two stages of the lifecycle. The *P. falciparum* cell traversal protein of ookinetes and sporozoites (PfCeITOS), independently identified by mining genomic [11] and expression [12] sequence databases, is a micronemal secreted-protein. This antigen has been implicated in host cell-traversal and invasion during both motile life-stages of the parasite, thus supporting its candidacy as a pre-erythrocytic target.

Initial studies in mice demonstrated protective efficacy against a heterologous *P. berghei* challenge using a codon-harmonized, *E. coli*-expressed PfCeITOS [13]. These antibodies recognized both *P. falciparum* and *P. berghei* sporozoites, and inhibited gliding motility and hepatocyte invasion *in vitro*. Recently, the contribution of antibodies and T cells as the effectors against parasites at the site of infection was verified using *In vivo* Imaging System (IVIS) [14]. In studies using an experimental clinical-grade adjuvant – a synthetic TLR4 agonist in a stable oil-in-water emulsion designed to enhance humoral and cell-mediated immunity (GLA-SE) – Th1-biased immune responses (with higher IgG2a antibodies, IFN-γ responses and long-lived antibody-secreting cells) were observed in BALB/c mice as compared to mice immunized with the same antigen in Montanide ISA720 [15]. However, when this formulation was tested in a first-in-human clinical trial, while safe and immunogenic, no protective efficacy was observed against controlled human malaria infection (CHMI) (J. Cowden, personal communication). A subsequent Phase Ia trial with PfCeITOS in GSK's AS01B adjuvant is currently ongoing (Clinicaltrials.gov NCT02174978).

Other vaccine strategies have assessed delivery of PfCeITOS using viral vectored vaccines in inbred and outbred mice, however these failed to protect against a challenge with chimeric *P. berghei* parasites expressing the PfCeITOS antigen [16]. Another study sought to combine multiple sporozoite targets, including the PfCeITOS antigen, to broaden humoral and cellular responses. Ferraro *et al.* evaluated a multi-subunit DNA-electroporation delivery in mice and non-human primates (NHP) [17], and reported plasmid-expressed PfCeITOS antigen-specific antibodies and T cell responses. Recently a chimeric-molecule, composed of three *P. falciparum* 3D7 pre-erythrocytic domains (PfCeITOS; PfCSP-thrombospondin-related-type-1-repeat domain (-TSR); and thrombospondin-related adhesion protein (PfTRAP)-TSR),

expressed in *Nicotiana benthamiana* and delivered in Gerbu MM adjuvant induced antibodies in mice that recognized methanol-fixed sporozoites and inhibited invasion of hepatocytes up to 35%, although the specific contribution of PfCelTOS-antibodies was not elucidated [18]. While early indications in preclinical animal studies are encouraging, the potential for efficacy induced by a PfCelTOS-based vaccine in humans is yet to be realized.

2.2. PfAMA1

Apical membrane antigen 1 (AMA1) is a micronemal protein that is secreted onto the surface of both merozoites and sporozoites [19–21]. Historically PfAMA1 has been a leading malaria vaccine candidate (see [22] for a detailed review) and antibodies to AMA1 in multiple *Plasmodium* species block merozoite invasion of RBC and sporozoite invasion of hepatocytes [21,23]. However, the high number of polymorphisms [24,25] and *in vitro* data showing a predominantly allele-specific inhibition of anti-PfAMA1 antibodies [26,27] have damped expectations. Approaches to vaccine design to try and overcome antigenic heterogeneity are reviewed elsewhere in this series [Powe et al.].

Despite promising data from NHP studies [28–30], a key question is whether a PfAMA1-based vaccine can protect humans. This has been evaluated by CHMI with homologous parasites in Phase I/Ia studies using protein- or viral vector-based vaccination strategies [31–33]. Disappointingly, none of these studies, as well as two recent Phase IIb field trials [34,35], showed any overall efficacy when using vaccines based on PfAMA1 alone. It should be noted that another study using a DNA prime – adenoviral boost regime reported 27% sterilizing efficacy against mosquito-bite CHMI in healthy US adults when using vectored vaccines encoding PfAMA1 and PfCSP [36]. Cellular immune responses against PfAMA1 were largely associated with protective outcome [36,37]. Moreover, in one of the field trials of a protein PfAMA1-based vaccine formulated in AS02A adjuvant, 64% efficacy against low frequency, 3D7 vaccine-type parasites, as defined by homology at 9 out of over 60 polymorphic sites, was also observed [35]. This efficacy was not observed when the same population was followed over the next malaria season despite sustained high antibody titers [38].

Lack of efficacy with PfAMA1-based vaccines alone, at least in the CHMI studies, cannot be attributed to polymorphisms in PfAMA1 given that vaccine-homologous parasites were used [31–33]. Notably the PfAMA1 vaccines have been tested with adjuvants such as AS01B and AS02A, which remain a leading delivery technology in humans for the induction of high antibody concentrations. Consequently, if insufficient antibody titers are the reason that PfAMA1 vaccines failed to protect, then there remains a significant challenge to develop clinically relevant ways of improving the magnitude of anti-PfAMA1-specific antibody [31,38]. However, another possible reason for the poor efficacy in humans could be due to the vaccines not inducing a threshold concentration of functional antibodies, despite the overall high anti-PfAMA1 titers. Indeed, it remains unknown, for now, what proportion of vaccine-induced PfAMA1 antibodies in humans can provide functional anti-parasitic activity. Recent efforts have largely aimed at enhancing strain-transcendent, neutralizing antibodies by incorporating multiple PfAMA1 alleles or mutagenesis to redirect the immune response toward conserved regions [39–44], and one ‘diversity covering’ (DiCo) approach has just entered Phase Ia testing in Europe (Clinicaltrials.gov NCT02014727). These approaches increase the repertoire of antibodies against multiple PfAMA1 alleles but do not, however, appear to enhance inhibition of homologous parasites. Therefore developing new approaches to boost the proportion of functional antibodies, and improve the so-called “quality” of the antibody response, against homologous parasites could help advance PfAMA1-based vaccines.

Plasmodium merozoite invasion of RBC requires interaction of AMA1 with a conserved 47 amino acid region of rhoptry neck protein 2 (RON2, a parasite protein secreted onto the surface of the RBC), leading to conformational changes in the AMA1 loop regions surrounding the hydrophobic pocket [45–47]. Although the importance of this interaction has been debated [48–50], antibodies that bind the AMA1 loops block AMA1–RON2 interaction and inhibit invasion [46,51,52]. Interestingly, many of the polymorphisms in PfAMA1 are present in loops surrounding the PfRON2 binding site [25], indicating immune selection and the importance of these antibodies in protection. Since this form of AMA1 in complex with RON2 is functional and possibly exposed on the surface of the merozoite during invasion, a subunit vaccine mimicking this structure could perhaps be better than AMA1 alone. Interestingly, mice vaccinated with the *Plasmodium yoelii* AMA1–RON2L complex, but not PyAMA1 alone, were protected against a virulent *P. yoelii* challenge despite inducing similar levels of anti-PyAMA1 antibodies [53]. Consistent with this, IgG from animals immunized with the complex also inhibited *P. falciparum* homologous parasites significantly more than IgG from animals receiving PfAMA1 alone, suggesting a qualitative shift in the antibody response, *i.e.* a higher proportion of vaccine-induced antibodies that are inhibitory [53]. Indeed, preclinical evaluation in *Aotus* monkeys indicates that vaccination with the complex provides significantly higher protection than PfAMA1 alone against a homologous FVO-strain challenge (PS, LHM, unpublished). These data suggest that a threshold level of functional, neutralizing antibodies could be induced by a PfAMA1–RON2L complex vaccine to confer protection in humans. Efforts are currently underway to assess whether this approach provides protection in humans, and if combining a multi-allele PfAMA1 vaccine in complex with RON2L can protect against both homologous and heterologous parasites. It is tempting to speculate that immune responses to such next-generation PfAMA1-based vaccines may be boosted through natural infections in malaria endemic populations where PfAMA1 is one of the more immunogenic antigens.

2.3. PfMSP1

P. falciparum merozoite surface protein 1 (PfMSP1), the major surface coat antigen on merozoites, has been extensively investigated as a blood-stage vaccine candidate, primarily based on reports that anti-PfMSP1 antibodies are associated with decreased risk of clinical malaria, albeit, in an allele-specific manner [54]. To date, numerous PfMSP1-based vaccine trials have been completed, with all candidates being considered safe and immunogenic [55]. However, no vaccine candidate comprising of any portion of PfMSP1 has shown either efficacy or reduction of parasite multiplication rates (PMR) following homologous CHMI [33,56,57], or following natural infection in Phase IIb field trials [58,59]. It should be noted that, unlike for the PfAMA1 protein vaccine discussed above, sieve analysis of the PfMSP1 field trial data has not been reported and could provide valuable insight. Such analyses are important in order to document the potential value of a vaccine candidate antigen, whereby a positive outcome then shifts the challenge to approaches for overcoming antigenic diversity.

Early strategies for PfMSP1 focused on antibody induction using subunit protein-in-adjuvant vaccines [59,60] in heterologous allelic combinations [61] and multi-subunit combinations [62]. More recent clinical strategies have incorporated viral vectored prime-boost regimens to broaden immunity toward functional CD4⁺/CD8⁺ T cell induction [63], and in multi-subunit combinations [33]. In the latter cases, induction of effector T cells was unable to overcome limitations in the induction of effective antibody levels. To further assess PfMSP1-antibody functionality, *in vitro* assays of parasite growth/invasion inhibition activity (GIA/IIA) were

performed on immune sera or purified immunoglobulins. In general, modest to low levels of GIA were detected from vaccinated malaria-naïve subjects.

While PfMSP1 vaccine development has largely yielded disappointing outcomes in clinical investigations, several new efforts are focused on alternate expression hosts to improve subunit structure [64,65]; on forming chimeric molecules to broaden allele- and target-specific immunity [66–69]; on PfMSP1-nanoparticle delivery platforms [70,71]; on aggregates and chemical-conjugates [72]; and on viral vectored vaccines in prime-boost regimens co-expressing molecular adjuvants [73]. Despite significant hurdles to their development and evaluation, some limited improvements in PfMSP1-specific antibody functionalities have been reported from animal studies. While these findings may be promising, it remains to be seen whether they are sufficient to exceed the limitations in antibody magnitude, specificity and functionality observed to-date in humans.

2.4. *PfRH5*

In recent years *P. falciparum* reticulocyte-binding protein homolog 5 (PfRH5) has emerged as a promising vaccine candidate antigen against the blood-stage merozoite [74] which, similar to PfMSP1 and PfAMA1, has been assessed using the standardized cell-independent *in vitro* assay of GIA. Antibodies induced by PfRH5 vaccination in preclinical *in vitro* studies have been shown to overcome two long-standing difficulties associated with other merozoite antigens: first, they can block erythrocyte invasion to high efficiency (with lower EC₅₀ in terms of antigen-specific antibody concentration than other known antigens [75]); and second, antibodies induced by monovalent vaccines cross-inhibit all *P. falciparum* lines and field isolates tested to-date [74–77]. Notably these antibodies have been raised by using full-length PfRH5 immunogens, in contrast to earlier work that failed to induce functional antibodies when using fragments of the antigen made in *E. coli* [78,79]. Generation of full-length PfRH5 protein proved particularly problematic, and thus the earliest promising results were achieved using viral vectored immunization [74], whereby antigen is expressed *in situ* from virally infected muscle cells [80]; also see Ewer et al. in this review series. Since that time, substantial progress has been made with reports of successful full-length PfRH5 protein production from numerous heterologous expression systems including mammalian HEK293 cells [81], *E. coli* [77,82], baculovirus-infected insect cells [83,84], wheatgerm [85], and *Drosophila* S2 stable cell lines [86], but notably not yeast-based systems.

Production of PfRH5 antigen in mammalian cells led to the identification of its RBC surface receptor, basigin, with which it forms a critical non-redundant interaction during invasion [87]. The PfRH5 gene is also refractory to genetic deletion [78,88], confirming the essential nature of its function, however, in the context of natural infection, PfRH5 does not appear to be a dominant target of naturally acquired immune responses [74,89–91]. The high degree of PfRH5 sequence conservation is thus associated with low-level natural immune pressure, but also functional constraints linked to basigin binding. Minimal amino acid substitutions in PfRH5 account for loss of basigin binding and/or host RBC tropism (linked to binding basigin orthologues from other species), suggesting the antigen may not easily escape vaccine-induced immune pressure [88,92,93].

Most recently high-level efficacy was reported for the first time against a stringent heterologous strain blood-stage challenge in an *in vivo* Aotus monkey-*P. falciparum* challenge model, following vaccination with viral vectors or PfRH5 protein produced from mammalian HEK293 cells [94]. Protection was strongly correlated with anti-PfRH5 serum IgG antibody concentration

and *in vitro* functional GIA [94], confirming the utility of this assay to predict *in vivo* protection and for future vaccine candidate down-selection. There is now significant momentum to progress PfRH5-based vaccines into clinical trials. Although the first candidate to enter the clinic is utilizing viral vectored delivery (Clinicaltrials.gov NCT02181088), at least one full-length protein immunogen has entered cGMP production in Oxford, UK using the *Drosophila* S2 cell expression platform [95]. With recent reports of the crystal structure of PfRH5 bound to basigin and neutralizing mouse monoclonal antibodies (mAbs) [84,86,96], future developments will likely see rationally designed second-generation protein immunogens seeking to focus antibody induction on critical areas of the molecule. It is likely PfRH5 immunogens will also be developed using various VLP technologies to maximize antibody induction, and the first VLP of bacteriophage MS2 isolated against an inhibitory mAb has already been reported [97]. VLP platforms are also reviewed elsewhere in this series [Wu et al.]. Furthermore, the recent elucidation of a protein complex containing PfRH5 and two binding partners – PfRH5-interacting protein (PfRipr) and the GPI-anchored cysteine-rich protective antigen/PfRH5-PfRipr membrane-anchoring protein (PfCyRPA/PfRRMAP) [98,99], suggests further opportunities to improve vaccine potency – both antigens elicit functional antibodies alone [82,98–100], and IgG responses induced in rats by PfRH5 and PfCyRPA proteins produced in *E. coli* have been shown to synergize [75,99].

2.5. *PfSERA5*

One family of proteases associated with the merozoite surface and known to be involved in the egress of *P. falciparum* merozoites from blood-stage schizonts is the large multigene family of serine repeat antigens (SERAs) [101,102]. Of nine members, PfSERA5 is strongly expressed in schizont stages (approximately 0.5–1.5% of the total mRNA) [103] and, together with PfSERA6, is refractory to deletion and essential for parasite growth [104–106]. PfSERA5-based vaccine candidates were shown to induce antibodies that either protected against blood stage infection *in vivo* [107] or inhibited parasite growth *in vitro* [108,109]. Recombinant proteins made from the N-terminal domains of PfSERA5 have been shown to be immunogenic and elicited antibodies that inhibited erythrocyte invasion and parasite replication *in vitro* and in animal models; as well as inversely correlate with parasite density and/or malaria symptoms in sero-epidemiological studies in Uganda and Solomon Islands (reviewed in [110]). It is still a challenge to elucidate the exact role(s) of PfSERA5 but selective inhibitors of subtilisin-like serine protease subtilase 1 (PfsUB1), an enzyme involved in the processing of PfSERA5, have been shown to inhibit merozoite egress and parasite maturation [111–115]. The significance of the tight temporal, yet extensive processing steps of PfSERA5 remain to be fully understood. In some studies, other than proteolysis [116], some regulatory roles (chaperone-like function or substrate recognition and binding) have also been suggested [114,117]. An immunological “smoke screen” or blocking of the complement pathway is also possible [118,119].

The SE36 vaccine candidate is a recombinant form of the PfSERA5 N-terminal domain without the polyserine repeats. Expressed in *E. coli*, there are two products under clinical trials: BK-SE36 with aluminum hydroxide gel [120] and a recent iteration, comprising of BK-SE36 and the TLR9 agonist CpG (BK-SE36/CpG) [121]. The BK-SE36 malaria vaccine showed a favorable safety profile in Japanese male adults and in a malaria-exposed population in Uganda aged 6–20 years old. Local adverse reactions were comparable to other alum-based vaccines: induration, tenderness, pain, swelling, erythema and redness were reported [120]. Immunogenicity analyses indicate that high seroconversion was achieved by vaccination of 1 mL BK-SE36 (equivalent to 100 µg

SE36 protein and 1 mg aluminum hydroxide gel) in malaria-naïve healthy Japanese adults and in individuals with low pre-existing anti-SE36 antibody in the malaria-exposed population [120]. Low seroconversion in malaria exposed adults might be interpreted as immunotolerance in this age group, as observed in other clinical trials [122,123]. Nevertheless, immunogenicity was remarkably high in the 6–10 year old age group in Uganda. In an ancillary analysis from follow-up of the Phase Ib study, vaccination with BK-SE36 was shown to confer over 70% protection against symptomatic malaria for one year [120]. Antibody titer changes and dynamics of malaria infection also suggest that antibody titers against SE36 were boosted after episodes of natural infection, at least for individuals where doubling of antibody titers from the pre-vaccination titer was observed Yagi, Horii et al. (unpublished). Additionally, analysis of *sera5* allele haplotype diversities and haplotype frequencies were similar between parasite isolates from infected vaccinees and the control group (Arisue et al., unpublished data). Importantly, unlike other blood-stage vaccine candidates, the N-terminal regions possessing inhibitory epitopes are intrinsically unstructured [119], thus strict tertiary structure may not be required to elicit protective antibodies. Further studies using the CpG adjuvant to improve the immunogenicity of the antigen is in Phase Ia clinical trial (Horii et al., unpublished), and formal Phase II efficacy testing of the SE36 candidate will be eagerly awaited.

2.6. *PfGLURP*, *PfMSP3* and *Pfs48/45*

Further efforts in the field have focused on the *P. falciparum* merozoite antigens glutamate-rich protein (*PfGLURP*) and *PfMSP3*, more recently combined with the gamete antigen *Pfs48/45*. Selection of these target antigens and subunit vaccine design was guided by observations made from studies of naturally acquired immunity (NAI), *in vitro* functional bioassays and assessment in preclinical/clinical studies. Expression of two recombinant subunit vaccine candidates to-date has relied on the use of *Lactococcus lactis* (a generally recognized as safe or 'GRAS' organism). These include GMZ2 (a fusion of *PfGLURP* and *PfMSP3*) targeting the asexual blood-stage and aimed at reducing the parasite load in order to confer protection against clinical malaria, and more recently *Pfs48/45*, aimed at targeting the parasite's sexual development within the mosquito and thus seeking to reduce parasite transmission.

GMZ2 is a hybrid protein [124] consisting of conserved domains of the two asexual blood stage antigens from *P. falciparum* – *GLURP_{27–500}* and *MSP3_{212–380}* [125,126], aimed to mimic pathogen components that induce premunition, a state of NAI against *P. falciparum* malaria [127]. The *PfGLURP* and *PfMSP3* components of GMZ2 were chosen to be combined as a hybrid protein based on a series of immuno-epidemiological studies from geographically diverse epidemiological settings [128–133] with some synergism observed between naturally occurring antibodies against both antigens [132]; functional *in vitro* studies [133,134]; and population genetic studies of malaria exposed children [135]. Notably the selection of these candidate antigens was prioritized on the basis of the ability of antigen-specific antibodies to elicit antibody-dependent cellular inhibition (ADCI) in conjunction with monocytes, as opposed to cell-independent neutralization in the assay of GIA as used to assess vaccines based on *PfMSP1*, *PfAMA1* and *PfRH5*. Clinical development of GMZ2 has focused on the use of an Alhydrogel (alum) adsorbed formulation which has proven to be safe and well tolerated in preclinical toxicology studies [136]. This GMZ2/alum formulation has been tested in three Phase Ia/b studies in (i) malaria-naïve German adults [137]; (ii) partially immune Gabonese adults [138]; and (iii) Gabonese children aged 1–5 years [139]. All these trials have shown GMZ2/alum to be safe, well tolerated and immunogenic. Recently, it was demonstrated that the GMZ2/alum formulation elicits antibody titers in humans which

are equivalent to those obtained after years of natural exposure [140]. It was therefore decided to test the GMZ2/alum formulation in a multicenter Phase IIb trial in African children to assess safety, tolerability and efficacy in the target population. Results from this trial are awaited.

The *Pfs48/45* protein is expressed during the sexual differentiation of the parasite into gametocytes [141] and consists of cysteine-rich domains with multiple disulfide bonds. These constitute distinct conformational B cell epitopes recognized by several mAbs with transmission-blocking activity (TBA) [142]. During their development in the human host, gametocytes remain intra-erythrocytic and are relatively sheltered from the effects of the immune system. However, once inside the mosquito midgut the parasite develops into extra-erythrocytic gametes, exposing *Pfs48/45* on their surface, where the antigen can be targeted by antibodies and other components of the blood meal [141]. Naturally acquired anti-*Pfs48/45* antibodies are present in endemic populations, and the occurrence of these antibodies is associated with TBA when tested in the standard membrane feeding assay (SMFA) [143–146]. Overcoming the challenges related to the recreation of the native conformation of *Pfs48/45* [147–154], recently led to the production of the carboxy-terminal 10C-fragment of *Pfs48/45* (containing three known epitopes for transmission-blocking antibodies) as a chimera with the N-terminal R0 region of *PfGLURP* [155]. This resulting chimeric protein elicited broadly inhibiting antibodies against both asexual- and transmission-stages of *P. falciparum*. Further variants with a truncated 10C region are now being explored and show promise in terms of improved yield and induction of functional antibodies in rats [156]. A combination vaccine with antigens from both asexual- and transmission-stages may provide both direct protection against clinical disease and indirect benefit by reducing the spread of the parasite in the population. The future assessment of the merits of such multi-stage subunit approaches in humans will be a key focus of research.

2.7. *Pfs25*

Pfs25, a 25-kDa surface antigen of zygotes and ookinetes is currently the most developed transmission-blocking vaccine (TBV) candidate in the pipeline and the only one that has been tested in human clinical trials [157], along with its ortholog *Pvs25* from *P. vivax* [158]. Anti-*Pfs25* antibodies induced in humans after vaccination with soluble *Pfs25* protein in Montanide ISA51 are functional in the *ex vivo* SMFA and significantly block the development of both laboratory strain and field isolates (from gamete donors) of *P. falciparum* [158].

To-date *Pfs25* has been successfully produced in a variety of expression systems as a soluble protein unlike the cysteine rich pre-fertilization targets (*Pfs48/45* and *Pfs230* region C) which have proven more difficult to express in heterologous systems [157]. The TBA of antibodies against *Pfs25* usually correlates with the antibody titer, and in humans the absolute concentration of anti-*Pfs25* specific IgG required to achieve significant blocking is high (86 µg/mL IC₅₀ in the SMFA) [159]. In order to achieve high antibody titers in humans, vaccine candidates will therefore likely require strong chemical adjuvants and/or highly immunogenic delivery platforms. The most potent chemical adjuvants can lead to unacceptable levels of reactogenicity, as reported in the Phase Ia clinical trial of a soluble *Pfs25*-Montanide ISA51 formulation [158]. Future trials of vaccine candidates with other leading adjuvants in clinical development, such as AS01B or GLA-SE, will hopefully show acceptable reactogenicity profiles.

There has been substantial recent interest in developing improved delivery platforms for *Pfs25* protein either by conjugating *Pfs25* to carrier proteins or displaying *Pfs25* on VLPs. Soluble *Pfs25* has been produced in *E. coli* after codon harmonization [160],

the wheatgerm cell-free system [161], mammalian HEK293 cells Nikolaeva, Biswas et al. (unpublished), plant-based *N. benthamiana* [162] and *Chlamydomonas reinhardtii* [163], and in yeast (*P. pastoris* and *S. cerevisiae*) [164,165]. To-date, protein produced in yeast is the best characterized and the one tested in human clinical trials [158].

Pfs25 has been conjugated to itself [166], NANP repeats of the PfCSP [167], or to carrier proteins like covalent conjugation to outer membrane protein complex (OMPC) of *Neisseria meningitidis* [168], exoprotein A of *Pseudomonas aeruginosa* (EPA) [169] and cholera toxin subunit B [170]. Studies in Oxford have recently fused Pfs25 to IMX313, a protein heptamerization technology [73,171], leading to the expression of a nanoparticle in *P. pastoris* and significantly improved antibody titers and TBA in preclinical studies Lee, Biswas et al. (unpublished). Indeed, most of these efforts have led to significant increase in anti-Pfs25 antibody titer and TBA. In the study where Pfs25 was conjugated to OMPC, the results were highly encouraging as the antibody response in macaques persisted at high-levels for over 18 months [168] – a highly desirable attribute for any vaccine seeking to block malaria transmission for prolonged periods of time. The Pfs25-EPA conjugate formulated with Alhydro-gel has now been tested in malaria-naïve adult volunteers in the USA, with extension to Phase Ib field trials in Mali underway. Most recently, a clinical study has begun in the USA to assess a combination of this vaccine with another consisting of EPA conjugated to a region of the gamete antigen Pfs230 (Clinicaltrials.gov NCT02334462). The Fraunhofer Institute has also developed a VLP by fusion of Pfs25 to the Alfalfa mosaic virus coat protein, expressed in *N. benthamiana*, which is also currently being tested in humans. The results of these most recent clinical trials of Pfs25-based conjugates are eagerly awaited.

3. Concluding remarks

The development of a highly effective vaccine against *Plasmodium* parasites has proved exceptionally challenging, but protein/adjuvant subunits have to-date provided at least one partially efficacious product based on the PfCSP antigen in the form of RTS,S/AS01B [8]. Protein vaccine candidates against other targets have proved disappointing in Phase IIa/b efficacy trials, but the continued need to innovate has driven much progress in terms of antigen design, expression, cGMP production and human delivery. Efficacy results from on-going trials of GMZ2 and SE36 remain eagerly awaited; improved formulations and iterations of PfMSP1, PfAMA1, Pfs25 and PfCelTOS are under active development or in clinical trials; and new antigens such as PfRH5, Pfs230 and Pfs48/45 amongst others are entering cGMP production or Phase Ia clinical testing. Nevertheless, it is likely that a highly effective vaccine seeking to prevent death, disease or transmission, as required by the recently updated Malaria Vaccine Technology Roadmap to 2030 [172], will necessitate new strategies; and key developments likely to be seen in the near future are outlined in Box 1. The next few years promise to be an exciting time as these new candidates, formulations and approaches are assessed in humans.

Conflict of interest statement

SJD is a named inventor on patent applications covering PfRH5-based vaccines, malaria vectored vaccines and immunization regimes. EA is a named inventor on patent applications relating to PfMSP1- and PfCelTOS-based vaccines. TH holds a patent for BK-SE36. PS and LHM are named inventors on patent applications covering PfAMA1–RON2L complex-based vaccines.

Box 1: Anticipated future developments for protein-based malaria vaccines.

- **Antigen Discovery:** New and promising vaccine candidate antigens from the sporozoite-, merozoite- and sexual-stage parasites will be discovered from numerous approaches making use of “-omic” datasets [5] [Doolan et al. in this review series]. Antigens that are conserved, essential, not necessarily dominant targets of naturally acquired immunity and yet antibody-susceptible would be attractive targets for protein-based vaccines.
- **Antigen Combinations:** These will be explored empirically and rationally, seeking to define combinations of antigens against the same or multiple lifecycle stages that can provide additive, or ideally synergistic, benefit in terms of protective efficacy [75,181].
- **Structure-based Immunogen Design:** Development of new protein-based immunogens will benefit from structural understanding of how human antibodies successfully block their parasitic targets. Focus may shift from antigen targets *per se* to ‘epitope-based’ targets, with structural biology guiding the design of improved peptide-based vaccines [182] [Patarroyo ME et al. companion paper]; or protein-based vaccines, as being currently explored for viral pathogens such as HIV, influenza and RSV [183,184].
- **New Protein Expression Platforms for cGMP Production:** It is likely that new heterologous expression systems will be developed to produce new-generation immunogens for malaria, complementing existing capabilities in bacterial- and yeast-based systems. Insect cell platforms have already been progressed for PfRH5 and VAR2CSA [95], and mammalian cell-based platforms have proved exceptionally valuable in preclinical studies for the expression of full-length malaria proteins [81].
- **Improved Protein Vaccine Delivery Platforms:** New generation protein-based vaccines will explore a range of novel delivery platforms seeking to improve antibody immunogenicity in humans. A range of VLP-, particle- or vesicle-based technologies will likely be tested for their ability to deliver arrayed antigen as a highly immunogenic composition. Mixed-modality prime-boost immunization regimes incorporating vectored- and protein-based components will seek to maximize both cellular and humoral immune responses [80,185,186]. Improved understanding of B cell and CD4⁺ T follicular helper cell responses [187,188] could guide the development of vaccine delivery platforms that can enhance the peak and/or longevity of the antibody response.
- **Adjuvants:** On-going development of new vaccine adjuvants, designed on the basis of improved understanding of innate immune sensing mechanisms, will likely be tested with protein-based malaria vaccines seeking high-titer antibody induction.
- **Assay Development and Quantitative Vaccine Assessment:** The on-going development of *in vitro/ex vivo* assays and assessment of their relationship to *in vivo* malaria protection will remain an important focus of research. The ability to quantitatively measure antigen-specific antibody concentrations and their related functional activity should allow for the prioritization of new antigens that are inherently more susceptible to antibodies [75,94,159,189], or the definition of immunogens that elicit qualitatively improved IgG responses [53].
- **CHMI Models:** The continued use of CHMI models in Phase IIa clinical trials will allow for rapid efficacy assessment of new protein vaccine candidates and formulations. Vaccines targeting the pre-erythrocytic stages can now be tested using the mosquito-bite or cryopreserved sporozoite (PfSPZ Challenge) models [190,191]. While the possible effect(s) of blood-stage vaccines on high-level parasitemia cannot be

explored in the context of CHMI for obvious safety reasons [192], on-going efforts are aiming to refine the use of the blood-stage CHMI model [193] to assess the impact of new blood-stage vaccines on the parasite multiplication rate (PMR) [194] prior to diagnosis by thick-film microscopy Payne, Draper et al. (unpublished). Other novel approaches using CHMI models, including sub-curative drug treatment regimes, should allow for gametocyte induction and testing of *P. falciparum* transmission-blocking vaccines. The development of cryopreserved sporozoites and blood-stage inocula is now enabling the first modern CHMI studies in malaria-endemic countries [195] and will allow for proof-of-concept vaccine testing in the target population, including individuals with existing degrees of natural immunity. The development of new *P. falciparum* parasite strains for CHMI [196,197], beyond the historical NF54 strain/3D7 clone, will enable more informative assessment of vaccines against heterologous parasites and more recent isolates; while the establishment of blood-stage inocula for *P. vivax* will allow expansion of efforts into vaccine testing against a second parasite species [198].

Disclaimer

"The authors' views are private and are not to be construed as official policy of the Department of Defense or the U.S. Army. Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 1996 edition."

Acknowledgements

SJD is a Jenner Investigator, a Lister Institute Research Prize Fellow and a UK Medical Research Council (MRC) Career Development Fellow [G1000527; this Fellowship is jointly funded by the UK MRC and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement]. EA acknowledges funding from the U.S. Military Infectious Diseases Research Program (MIDRP) and the U.S. Agency for International Development (USAID) through an Interagency Agreement (IAA). TH acknowledges funding from Grant-in-Aid for Scientific Research (A) [grant number 24249024] from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and Global Health Innovative Technology Fund [GHIT RFP 2013-001]. LHM and PS are supported by the Intramural Research Program of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA; and also acknowledge support from USAID. MT acknowledges funding from the EU FP7 Seventh Framework Program Theme Health-2009-2.3.2-5 [grant 242079]; the Danish Council for Strategic research [grant 13127]; and the European and Developing Countries Clinical Trials Partnership (EDCTP) [grant IP.2007.3110.001]. SB is a NDM Leadership Fellow and Junior Research Fellow of St Catherine's College, Oxford University.

References

- [1] Hill AV. Vaccines against malaria. *Philos Trans R Soc Lond B Biol Sci* 2011;366(October (1579)):2806–14.
- [2] Mehlhorn C, Boni E, Buckner FS, Engel L, Feist T, Gelb MH, et al. Heterologous expression of proteins from *Plasmodium falciparum*: results from 1000 genes. *Mol Biochem Parasitol* 2006;148(August (2)):144–60.
- [3] Coler RN, Carter D, Friede M, Reed SG. Adjuvants for malaria vaccines. *Parasite Immunol* 2009;31(September (9)):520–8.
- [4] Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. *Nat Immunol* 2008;9(July (7)):725–32.
- [5] Coppel RL. Vaccinating with the genome: a Sisyphean task? *Trends Parasitol* 2009;25(May (5)):205–12.
- [6] Birkett AJ, Moorthy VS, Loucq C, Chitnis CE, Kaslow DC. Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities. *Vaccine* 2013;31(April (Suppl. 2)):B233–43.
- [7] Casares S, Brumeau TD, Richie TL. The RTS,S malaria vaccine. *Vaccine* 2010;28(July (31)):4880–94.
- [8] RTS SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. *Lancet* 2015;386(July (9988)):31–45.
- [9] Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. *Hum Vaccin* 2010;6(January (1)):90–6.
- [10] Ballou WR. The development of the RTS,S malaria vaccine candidate: challenges and lessons. *Parasite Immunol* 2009;31(September (9)):492–500.
- [11] Doolan DL, Southwood S, Freilich DA, Sidney J, Gruber NL, Shatney L, et al. Identification of *Plasmodium falciparum* antigens by antigenic analysis of genomic and proteomic data. *Proc Natl Acad Sci U S A* 2003;100(August (17)):9952–7.
- [12] Kariu T, Ishino T, Yano K, Chinzei Y, Yuda M. CelTOS a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. *Mol Microbiol* 2006;59(March (5)):1369–79.
- [13] Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, et al. Immunization with pre-erythrocytic antigen CelTOS from *Plasmodium falciparum* elicits cross-species protection against heterologous challenge with *Plasmodium berghei*. *PLoS ONE* 2010;5(8):e12294.
- [14] Bergmann-Leitner E, Li Q, Cardha D, O'Neill MT, Ockenhouse CF, Hickman M, et al. Protective immune mechanisms against pre-erythrocytic forms of *Plasmodium berghei* depend on target antigen. *Trials Vaccinol* 2014;3:6–10.
- [15] Fox CB, Baldwin SL, Vedvick TS, Angov E, Reed SG. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. *Clin Vaccin Immunol* 2012;19(October (10)):1633–40.
- [16] Longley RJ, Salman AM, Cottingham MG, Ewer K, Janse CJ, Khan SM, et al. Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. *Sci Rep* 2015;5:11820.
- [17] Ferraro B, Talbott KT, Balakrishnan A, Cisper N, Morrow MP, Hutnick NA, et al. Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. *Infect Immun* 2013;81(October (10)):3709–20.
- [18] Voepel N, Boes A, Edge G, Beiss V, Kapelski S, Reimann A, et al. Malaria vaccine candidate antigen targeting the pre-erythrocytic stage of *Plasmodium falciparum* produced at high level in plants. *Biotechnol J* 2014;9(November (11)):1435–45.
- [19] Bannister LH, Hopkins JM, Dluzewski AR, Margos G, Williams IT, Blackman MJ, et al. *Plasmodium falciparum* apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite development. *J Cell Sci* 2003;116(September (Pt 18)):3825–34.
- [20] Srinivasan P, Abraham EG, Ghosh AK, Valenzuela J, Ribeiro JM, Dimopoulos G, et al. Analysis of the *Plasmodium* and *Anopheles* transcriptomes during oocyst differentiation. *J Biol Chem* 2004;279(February (7)):5581–7.
- [21] Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, Bodescot M, et al. A role for apical membrane antigen 1 during invasion of hepatocytes by *Plasmodium falciparum* sporozoites. *J Biol Chem* 2004;279(March (10)):9490–6.
- [22] Remarque Ej, Faber BW, Kocken CH, Thomas AW. Apical membrane antigen 1: a malaria vaccine candidate in review. *Trends Parasitol* 2008;24(February (2)):74–84.
- [23] Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. *Infect Immun* 2001;69(May (5)):3286–94.
- [24] Marshall VM, Zhang L, Anders RF, Coppel RL. Diversity of the vaccine candidate AMA-1 of *Plasmodium falciparum*. *Mol Biochem Parasitol* 1996;77(April (1)):109–13.
- [25] Bai T, Becker M, Gupta A, Strike P, Murphy VJ, Anders RF, et al. Structure of AMA1 from *Plasmodium falciparum* reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. *Proc Natl Acad Sci U S A* 2005;102(September (36)):12736–41.
- [26] Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, et al. In vitro studies with recombinant *Plasmodium falciparum* apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. *Infect Immun* 2002;70(December (12)):6948–60.
- [27] Healer J, Murphy V, Hodder AN, Masciantonio R, Gemmill AW, Anders RF, et al. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in *Plasmodium falciparum*. *Mol Microbiol* 2004;52(April (1)):159–68.
- [28] Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH. Vaccination of monkeys with recombinant *Plasmodium falciparum* apical membrane antigen 1 confers protection against blood-stage malaria. *Infect Immun* 2002;70(December (12)):6961–7.
- [29] Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. *PLoS ONE* 2009;4(12):e8138.
- [30] Mahdi Abdel Hamid M, Remarque Ej, van Duivenvoorde LM, van der Werff N, Walraven V, Faber BW, et al. Vaccination with *Plasmodium knowlesi* AMA1 formulated in the novel adjuvant co-vaccine HT protects against blood-stage challenge in rhesus macaques. *PLoS ONE* 2011;6(5):e20547.

- [31] Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. *PLoS ONE* 2009;4(4):e5254.
- [32] Duncan CJ, Sheehy SH, Ewer KJ, Douglas AD, Collins KA, Halstead FD, et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. *PLoS ONE* 2011;6(7):e22271.
- [33] Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. *Mol Ther* 2012;20(December (12)):2355–68.
- [34] Ouattara A, Mu J, Takala-Harrison S, Saye R, Sagara I, Dicko A, et al. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. *Malar J* 2010;9:175.
- [35] Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, et al. A field trial to assess a blood-stage malaria vaccine. *N Engl J Med* 2011;365(September (11)):1004–13.
- [36] Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, et al. DNA prime/adenovirus boost malaria vaccine encoding *P. falciparum* CSP and AMA1 induces sterile protection associated with cell-mediated immunity. *PLOS ONE* 2013;8(2):e55571.
- [37] Sedegah M, Hollingdale MR, Farooq F, Ganeshan H, Belmonte M, Kim Y, et al. Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes. *PLOS ONE* 2014;9(9):e106241.
- [38] Laurens MB, Thera MA, Coulibaly D, Ouattara A, Kone AK, Guindo AB, et al. Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in Malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. *PLOS ONE* 2013;8(11):e79323.
- [39] Remarque EJ, Faber BW, Kocken CH, Thomas AW. A diversity-covering approach to immunization with *Plasmodium falciparum* apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. *Infect Immun* 2008;76(June (6)):2660–70.
- [40] Dutta S, Dlugosz LS, Clayton JW, Pool CD, Haynes JD, Gasser RA, 3rd, et al. Alanine mutagenesis of the primary antigenic escape residue cluster, c1, of apical membrane antigen 1. *Infect Immun* 2010;78(February (2)):661–71.
- [41] Miura K, Herrera R, Diouf A, Zhou H, Mu J, Hu Z, et al. Overcoming allelic specificity by immunization with five allelic forms of *Plasmodium falciparum* apical membrane antigen 1. *Infect Immun* 2013;81(May (5)):1491–501.
- [42] Dutta S, Dlugosz LS, Drew DR, Ge X, Ababacar D, Rovira YI, et al. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. *PLoS Pathog* 2013;9(12):e1003840.
- [43] Terheggen U, Drew DR, Hodder AN, Cross NJ, Mugenyi CK, Barry AE, et al. Limited antigenic diversity of *Plasmodium falciparum* apical membrane antigen 1 supports the development of effective multi-allele vaccines. *BMC Med* 2014;12(October (1)):183.
- [44] Harris KS, Adda CG, Khore M, Drew DR, Valentini-Gatt A, Fowkes FJ, et al. Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1. *Infect Immun* 2014;82(November (11)):4707–17.
- [45] Lamarque M, Besteiro S, Papoin J, Roques M, Vulliez-Le Normand B, Morlon-Guyot J, et al. The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites. *PLoS Pathog* 2011;7(2):e1001276.
- [46] Srinivasan P, Beatty WL, Diouf A, Herrera R, Ambroggio X, Moch JK, et al. Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion. *Proc Natl Acad Sci U S A* 2011;108(August (32)):13275–80.
- [47] Tonkin ML, Roques M, Lamarque MH, Pugniere M, Douguet D, Crawford J, et al. Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide. *Science* 2011;333(July (6041)):463–7.
- [48] Giovannini D, Spath S, Lacroix C, Perazzi A, Bargieri D, Lagal V, et al. Independent roles of apical membrane antigen 1 and rhoptry neck proteins during host cell invasion by apicomplexa. *Cell Host Microbe* 2011;10(December (6)):591–602.
- [49] Bargieri DY, Andenmatten N, Lagal V, Thibierge S, Whitelaw JA, Tardieu I, et al. Apical membrane antigen 1 mediates apicomplexan parasite attachment but is dispensable for host cell invasion. *Nat Commun* 2013;4:2552.
- [50] Harvey KL, Yap A, Gilson PR, Cowman AF, Crabb BS. Insights and controversies into the role of the key apicomplexan invasion ligand, Apical Membrane Antigen 1. *Int J Parasitol* 2014;44(October (12)):853–7.
- [51] Coley AM, Gupta A, Murphy VJ, Bai T, Kim H, Foley M, et al. Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody. *PLoS Pathog* 2007;3(September (9)):1308–19.
- [52] Collins CR, Withers-Martinez C, Hackett F, Blackman MJ. An inhibitory antibody blocks interactions between components of the malarial invasion machinery. *PLoS Pathog* 2009;5(January (1)):e1000273.
- [53] Srinivasan P, Ekanem E, Diouf A, Tonkin ML, Miura K, Boulanger MJ, et al. Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. *Proc Natl Acad Sci U S A* 2014;111(July (28)):10311–6.
- [54] Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of *Plasmodium falciparum* malaria: a systematic review and meta-analysis. *PLoS Med* 2010;7(1):e1000218.
- [55] Goodman AL, Draper SJ. Blood-stage malaria vaccines – recent progress and future challenges. *Ann Trop Med Parasitol* 2010;104(April (3)):189–211.
- [56] Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, et al. Update on the clinical development of candidate malaria vaccines. *Am J Trop Med Hyg* 2004;71(August (2 Suppl.)):239–47.
- [57] Schwartz L, Brown GV, Genton B, Moorthy VS. A review of malaria vaccine clinical projects based on the WHO rainbow table. *Malar J* 2012;11:11.
- [58] Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against *Plasmodium falciparum* in Papua New Guinean children. *Vaccine* 2003;22(December (1)):30–41.
- [59] Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. *PLoS ONE* 2009;4(3):e4708.
- [60] Otsuka N, Angov E, Bergmann-Leitner E, Koehn M, Khan F, Bennett J, et al. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen *Plasmodium falciparum* FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01. *Malar J* 2013;12:29.
- [61] Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, Fay MP, et al. Phase 1 trial of the *Plasmodium falciparum* blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. *PLoS ONE* 2010;5(1):e8787.
- [62] Ellis RD, Wu Y, Martin LB, Shaffer D, Miura K, Aebig J, et al. Phase 1 study in malaria naive adults of BSAM2/Alhydrogel(R)+CPG 7909, a blood stage vaccine against *P. falciparum* malaria. *PLoS ONE* 2012;7(10):e46094.
- [63] Biswas S, Choudhary P, Elias SC, Miura K, Milne KH, de Cassan SC, et al. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. *PLOS ONE* 2014;9(9):e107903.
- [64] Nurul AA, Norazmi MN. Immunogenicity and in vitro protective efficacy of recombinant *Mycobacterium bovis* bacille Calmette Guerin(rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of *Plasmodium falciparum*. *Parasitol Res* 2011;108(April (4)):887–97.
- [65] Cowan GJ, Bockau U, Eleni-Muus J, Aldag I, Samuel K, Creasey AM, et al. A novel malaria vaccine candidate antigen expressed in *Tetrahymena thermophila*. *PLOS ONE* 2014;9(1):e87198.
- [66] Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, et al. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of *Plasmodium falciparum* merozoite surface protein-1 and the innate immunity agonist FlcI flagellin of *Salmonella typhimurium*. *Vaccine* 2010;28(April (16)):2818–26.
- [67] Alaro JR, Partridge A, Miura K, Diouf A, Lopez AM, Angov E, et al. A chimeric *Plasmodium falciparum* merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies. *Infect Immun* 2013;81(October (10)):3843–54.
- [68] Mazumdar S, Mukherjee P, Yazdani SS, Jain SK, Mohammed A, Chauhan VS. *Plasmodium falciparum* merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response. *Infect Immun* 2010;78(February (2)):872–83.
- [69] Faber BW, Younis S, Remarque EJ, Rodriguez Garcia R, Riasat V, Walraven V, et al. Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines. *Infect Immun* 2013;81(May (5)):1479–90.
- [70] Pusic K, Xu H, Stridiron A, Aguilar Z, Wang A, Hui G. Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies. *Vaccine* 2011;29(November (48)):8898–908.
- [71] Pusic K, Aguilar Z, McLoughlin J, Kobuch S, Xu H, Tsang M, et al. Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine. *FASEB J: Offi Publ Feder Am Soc Exp Biol* 2013;27(March (3)):1153–66.
- [72] Qian F, Reiter K, Zhang Y, Shimp Jr RL, Nguyen V, Aebig JA, et al. Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa *Plasmodium falciparum* merozoite surface protein-1. *PLoS ONE* 2012;7(6):e36996.
- [73] Forbes EK, de Cassan SC, Llewellyn D, Biswas S, Goodman AL, Cottingham MG, et al. T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of c4b-binding protein. *PLoS ONE* 2012;7(9):e44943.
- [74] Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL, et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. *Nat Commun* 2011;2:601.
- [75] Williams AR, Douglas AD, Miura K, Illingworth JJ, Choudhary P, Murungi LM, et al. Enhancing blockade of *Plasmodium falciparum* erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. *PLoS Pathog* 2012;8(November (11)):e1002991.
- [76] Bustamante LY, Bartholdson SJ, Crosnier C, Campos MG, Wanaguru M, Nguon C, et al. A full-length recombinant *Plasmodium falciparum* PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. *Vaccine* 2013;31(January (2)):373–9.
- [77] Reddy KS, Pandey AK, Singh H, Sahar T, Emmanuel A, Chitnis CE, et al. Bacterially expressed full-length recombinant *Plasmodium falciparum* RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies. *Infect Immun* 2014;82(January (1)):152–64.
- [78] Baum J, Chen L, Healer J, Lopaticki S, Boyle M, Triglia T, et al. Reticulocyte-binding protein homologue 5 – an essential adhesin involved

- in invasion of human erythrocytes by *Plasmodium falciparum*. *Int J Parasitol* 2009;39(February (3)):371–80.
- [79] Rodriguez M, Lustigman S, Montero E, Oksov Y, Lobo CA. PFRH5: a novel reticulocyte-binding family homolog of plasmodium falciparum that binds to the erythrocyte, and an investigation of its receptor. *PLoS ONE* 2008;3(10):e3300.
- [80] de Cassan SC, Draper SJ. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. *Expert Rev Vaccin* 2013;12(April (4)):365–78.
- [81] Crosnier C, Wanaguru M, McDade B, Osier FH, Marsh K, Rayner JC, et al. A library of functional recombinant cell-surface and secreted *P. falciparum* merozoite proteins. *Mol Cell Proteom* 2013;12(December (12)):3976–86.
- [82] Chiu CY, Healer J, Thompson JK, Chen L, Kaul A, Savergave L, et al. Association of antibodies to *Plasmodium falciparum* reticulocyte binding protein homolog 5 with protection from clinical malaria. *Front Microbiol* 2014;5:314.
- [83] Patel SD, Ahoudi AD, Bei AK, Dieye TN, Mboup S, Harrison SC, et al. *Plasmodium falciparum* merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. *J Infect Dis* 2013;208(November (10)):1679–87.
- [84] Chen L, Xu Y, Healer J, Thompson JK, Smith BJ, Lawrence MC, et al. Crystal structure of PfRh5, an essential *P. falciparum* ligand for invasion of human erythrocytes. *eLife* 2014;3.
- [85] Ord RL, Rodriguez M, Yamasaki T, Takeo S, Tsuboi T, Lobo CA. Targeting sialic acid dependent and independent pathways of invasion in *Plasmodium falciparum*. *PLoS ONE* 2012;7(1):e30251.
- [86] Wright KE, Hjerrild KA, Bartlett J, Douglas AD, Jin J, Brown RE, et al. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. *Nature* 2014;515(November (7527)):427–30.
- [87] Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, Uchikawa M, et al. Basigin is a receptor essential for erythrocyte invasion by *Plasmodium falciparum*. *Nature* 2011;480(December (7378)):534–7.
- [88] Hayton K, Gaur D, Liu A, Takahashi J, Henschen B, Singh S, et al. Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of *Plasmodium falciparum* invasion. *Cell Host Microbe* 2008;4(July (1)):40–51.
- [89] Villasis E, Lopez-Perez M, Torres K, Gamboa D, Neyra V, Bendezu J, et al. Anti-*Plasmodium falciparum* invasion ligand antibodies in a low malaria transmission region, Loreto, Peru. *Malar J* 2012;11:361.
- [90] Tran TM, Ongoba A, Coursen J, Crosnier C, Diouf A, Huang CY, et al. Naturally acquired antibodies specific for *Plasmodium falciparum* reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. *J Infect Dis* 2014;209(March (5)):789–98.
- [91] Osier FH, Mackinnon MJ, Crosnier C, Fegan G, Kamuyu G, Wanaguru M, et al. New antigens for a multicomponent blood-stage malaria vaccine. *Sci Transl Med* 2014;6(July (24)):247ra102.
- [92] Hayton K, Dumoulin P, Henschen B, Liu A, Papakriivos J, Wellens TE. Various PFRH5 polymorphisms can support *Plasmodium falciparum* invasion into the erythrocytes of owl monkeys and rats. *Mol Biochem Parasitol* 2013;187(February (2)):103–10.
- [93] Wanaguru M, Liu W, Hahn BH, Rayner JC, Wright GJ. RH5-Basigin interaction plays a major role in the host tropism of *Plasmodium falciparum*. *Proc Natl Acad Sci U S A* 2013;110(December (51)):20735–40.
- [94] Douglas AD, Baldeviano GC, Lucas CM, Lugo-Roman LA, Crosnier C, Bartholdson SJ, et al. A PFRH5-based vaccine is efficacious against heterologous strain blood-stage *Plasmodium falciparum* infection in aotus monkeys. *Cell Host Microbe* 2015;17(January (1)):130–9.
- [95] Dyring C. Optimising the drosophila S2 expression system for production of therapeutic vaccines. *BioProcess J* 2011;10(2):28–35.
- [96] Douglas AD, Williams AR, Knuepfer E, Illingworth JJ, Furze JM, Crosnier C, et al. Neutralization of *Plasmodium falciparum* merozoites by antibodies against PfRH5. *J Immunol* 2014;192(January (1)):245–58.
- [97] Ord RL, Caldeira JC, Rodriguez M, Noe A, Chackerian B, Peabody DS, et al. A malaria vaccine candidate based on an epitope of the *Plasmodium falciparum* RH5 protein. *Malar J* 2014;13(August (1)):326.
- [98] Chen L, Lopaticki S, Riglar DT, Dekiwadiya C, Uboldi AD, Tham WH, et al. An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by *Plasmodium falciparum*. *PLoS Pathog* 2011;7(September (9)):e1002199.
- [99] Reddy KS, Amlabu E, Pandey AK, Mitra P, Chauhan VS, Gaur D. Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for *Plasmodium falciparum* erythrocyte invasion. *Proc Natl Acad Sci U S A* 2015;112(January (4)):1179–84.
- [100] Dreyer AM, Matile H, Papastogiannidis P, Kamber J, Favuzza P, Voss TS, et al. Passive immunoprotection of *Plasmodium falciparum*-infected mice designates the CyRPA as candidate malaria vaccine antigen. *J Immunol* 2012;May.
- [101] Arisue N, Kawai S, Hirai M, Palacpac NM, Jia M, Kaneko A, et al. Clues to evolution of the SERA multigene family in 18 Plasmodium species. *PLoS ONE* 2011;6(3):e17775.
- [102] Cowman AF, Berry D, Baum J. The cellular and molecular basis for malaria parasite invasion of the human red blood cell. *J Cell Biol* 2012;198(September (6)):961–71.
- [103] Aoki S, Li J, Itagaki S, Okech BA, Egwang TG, Matsuoka H, et al. Serine repeat antigen (SERAs) is predominantly expressed among the SERA multigene family of *Plasmodium falciparum*, and the acquired antibody titers correlate with serum inhibition of the parasite growth. *J Biol Chem* 2002;277(December (49)):47533–40.
- [104] Miller SK, Good RT, Drew DR, Delorenzi M, Sanders PR, Hodder AN, et al. A subset of *Plasmodium falciparum* SERA genes are expressed and appear to play an important role in the erythrocytic cycle. *J Biol Chem* 2002;277(December (49)):47524–32.
- [105] McCoubrie JE, Miller SK, Sargeant T, Good RT, Hodder AN, Speed TP, et al. Evidence for a common role for the serine-type *Plasmodium falciparum* serine repeat antigen proteases: implications for vaccine and drug design. *Infect Immun* 2007;75(December (12)):5565–74.
- [106] Ruecker A, Shea M, Hackett F, Suarez C, Hirst EM, Milutinovic K, et al. Proteolytic activation of the essential parasitophorous vacuole cysteine protease SERA6 accompanies malaria parasite egress from its host erythrocyte. *J Biol Chem* 2012;287(November (45)):37949–63.
- [107] Perrin LH, Merkli B, Loche M, Chizzolini C, Smart J, Richle R. Antimalarial immunity in Saimiri monkeys. Immunization with surface components of asexual blood stages. *J Exp Med* 1984;160(August (2)):441–51.
- [108] Chulay JD, Lyon JA, Haynes JD, Meierovics AI, Atkinson CT, Aikawa M. Monoclonal antibody characterization of *Plasmodium falciparum* antigens in immune complexes formed when schizonts rupture in the presence of immune serum. *J Immunol* 1987;139(October (8)):2768–74.
- [109] Kanodia S, Kumar G, Rizzi L, Pedretti A, Hodder AN, Romeo S, et al. Synthetic peptides derived from the C-terminal 6 kDa region of *Plasmodium falciparum* SERAS inhibit the enzyme activity and malaria parasite development. *Biochim Biophys Acta* 2014;1840(September (9)):2765–75.
- [110] Palacpac NM, Arisue N, Tougan T, Ishii KJ, Horii T. *Plasmodium falciparum* serine repeat antigen 5 (SE36) as a malaria vaccine candidate. *Vaccine* 2011;29(August (35)):5837–45.
- [111] Yeoh S, O'Donnell RA, Koussis K, Dluzewski AR, Ansell KH, Osborne SA, et al. Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes. *Cell* 2007;131(December (6)):1072–83.
- [112] Arastu-Kapur S, Ponder EL, Fonovic UP, Yeoh S, Yuan F, Fonovic M, et al. Identification of proteases that regulate erythrocyte rupture by the malaria parasite *Plasmodium falciparum*. *Nat Chem Biol* 2008;4(March (3)):203–13.
- [113] Silmon de Monerri NC, Flynn HR, Campos MG, Hackett F, Koussis K, Withers-Martinez C, et al. Global identification of multiple substrates for *Plasmodium falciparum* SUB1, an essential malarial processing protease. *Infect Immun* 2011;79(March (3)):1086–97.
- [114] Alam A, Chauhan VS. Inhibitory potential of prodomain of *Plasmodium falciparum* protease serine repeat antigen 5 for asexual blood stages of parasite. *PLoS ONE* 2012;7(1):e30452.
- [115] Agarwal S, Singh MK, Garg S, Chitnis CE, Singh S. Ca(2+)-mediated exocytosis of subtilisin-like protease 1: a key step in egress of *Plasmodium falciparum* merozoites. *Cell Microbiol* 2013;15(June (6)):910–21.
- [116] Hodder AN, Drew DR, Epa VC, Delorenzi M, Bourgon R, Miller SK, et al. Enzymic, phylogenetic, and structural characterization of the unusual papain-like protease domain of *Plasmodium falciparum* SERA5. *J Biol Chem* 2003;278(November (48)):48169–77.
- [117] Putrianti ED, Schmidt-Christensen A, Arnold I, Heussler VT, Matuschewski K, Silvie O. The *Plasmodium* serine-type SERA proteases display distinct expression patterns and non-essential in vivo roles during life cycle progression of the malaria parasite. *Cell Microbiol* 2010;12(June (6)):725–39.
- [118] Pang XL, Horii T. Complement-mediated killing of *Plasmodium falciparum* erythrocytic schizont with antibodies to the recombinant serine repeat antigen (SERAs). *Vaccine* 1998;16(August (13)):1299–305.
- [119] Yagi M, Bang G, Tougan T, Palacpac NM, Arisue N, Aoshi T, et al. Protective epitopes of the *Plasmodium falciparum* SERAS malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences. *PLOS ONE* 2014;9(6):e98460.
- [120] Palacpac NM, Ntege E, Yeka A, Balikagala B, Suzuki N, Shirai H, et al. Phase 1b randomized trial and follow-up study in uganda of the blood-stage malaria vaccine candidate BK-SE36. *PLoS ONE* 2013;8(5):e64073.
- [121] Tougan T, Aoshi T, Coban C, Katakai Y, Kai C, Yasutomi Y, et al. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models. *Hum Vaccin Immunother* 2013;9(February (2)):283–90.
- [122] Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, et al. Safety and immunogenicity of the *Plasmodium falciparum* merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. *Vaccine* 2007;25(March (14)):2723–32.
- [123] Sirima SB, Tiono AB, Ouedraogo A, Diarra A, Ouedraogo AL, Yaro JB, et al. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12–24 months-old Burkinabe children. *PLOS ONE* 2009;4(10):e7549.
- [124] Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, et al. A *Plasmodium falciparum* GLURP-MSP3 chimeric protein: expression in *Lactococcus lactis*, immunogenicity and induction of biologically active antibodies. *Vaccine* 2004;22(March (9–10)):1188–98.
- [125] Stricker K, Vuust J, Jepsen S, Oeuvray C, Theisen M. Conservation and heterogeneity of the Glutamate-rich protein (GLURP) among field isolates and laboratory lines of *Plasmodium falciparum*. *Mol Biochem Parasitol* 2000;111:123–30.
- [126] Roussillon C, Oeuvray C, Muller-Graf C, Tall A, Rogier C, Trape JF, et al. Long-term clinical protection from *falciparum* malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. *PLoS Med* 2007;4(November (11)):e320.

- [127] Druilhe P, Perignon JL. A hypothesis about the chronicity of malaria infection. *Parasitol Today* 1997;13:353–7.
- [128] Dodo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, Jepsen S, et al. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against *Plasmodium falciparum* malaria. *J Infect Dis* 2000;181(3):1202–5.
- [129] Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P. Cytophilic immunoglobulin responses to *Plasmodium falciparum* glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. *Infect Immun* 2000;68(5):2617–20.
- [130] Theisen M, Soe S, Jessing SG, Okkels LM, Danielsen S, Oeuvray C, et al. Identification of a major B-cell epitope of the *Plasmodium falciparum* glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing. *Vaccine* 2000;19(September (2–3)):204–12.
- [131] Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB, et al. Humoral responses to *Plasmodium falciparum* blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. *Infect Immun* 2008;76(February (2)):759–66.
- [132] Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. *Infect Immun* 2004;72(January (1)):247–52.
- [133] Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote *Plasmodium falciparum* killing by cooperation with blood monocytes. *Blood* 1994;84(September (5)):1594–602.
- [134] Theisen M, Soe S, Oeuvray C, Thomas AW, Vuust J, Danielsen S, et al. The glutamate-rich protein (GLURP) of *Plasmodium falciparum* is a target for antibody-dependent monocyte-mediated inhibition of parasite growth *in vitro*. *Infect Immun* 1998;66(1):11–7.
- [135] Adu B, Jepsen MP, Gérds TA, Kyei-Baafour E, Christiansen M, Dodo D, et al. Fc gamma receptor 3B (FCGR3B-c.233C>A-rs5030738) polymorphism modifies the protective effect of malaria specific antibodies in Ghanaian children. *J Infect Dis* 2014;209(January (2)):285–9.
- [136] Carvalho LJ, Alves FA, Bianco Jr C, Oliveira SG, Zanini GM, Soe S, et al. Immunization of *Saimiri sciureus* monkeys with a recombinant hybrid protein derived from the *Plasmodium falciparum* antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants. *Clin Diagn Lab Immunol* 2005;12(2):242–8.
- [137] Esen M, Kremsner PG, Schleucher R, Gassler M, Imoukhuede EB, Imbault N, et al. Safety and immunogenicity of GMZ2 – a MSP3-GLURP fusion protein malaria vaccine candidate. *Vaccine* 2009;27(November (49)):6862–8.
- [138] Mordmuller B, Szywony K, Greutelaers B, Esen M, Mewono L, Treut C, et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. *Vaccine* 2010;28(September (41)):6698–703.
- [139] Belard S, Issifou S, Houkpatin AB, Schaumburg F, Ngoa UA, Esen M, et al. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. *PLoS ONE* 2011;6(7):e22525.
- [140] Jepsen MP, Jogdand PS, Singh SK, Esen M, Christiansen M, Issifou S, et al. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas. *J Infect Dis* 2013;208(August (3)):479–88.
- [141] Vermeulen AN, Ponnudurai T, Beckers PJ, Verhave JP, Smits MA, Meuwissen JH. Sequential expression of antigens on sexual stages of *Plasmodium falciparum* accessible to transmission-blocking antibodies in the mosquito. *J Exp Med* 1985;162(November (5)):1460–76.
- [142] Ouchkourou N, Vermunt A, Jansen J, Kaan A, Roeffen W, Teelen K, et al. Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies. *J Biol Chem* 2007;282(June (23)):17148–56.
- [143] Bousema JT, Drakeley CJ, Kihonda J, Hendriks JC, Akim NI, Roeffen W, et al. A longitudinal study of immune responses to *Plasmodium falciparum* sexual stage antigens in Tanzanian adults. *Parasite Immunol* 2007;29(June (6)):309–17.
- [144] Ouedraogo AL, Roeffen W, Luty AJ, de Vlas SJ, Nebie I, Ilboudo-Sanogo E, et al. Naturally acquired immune responses to *Plasmodium falciparum* sexual stage antigens Pfs48/45 and Pfs230 in an area of seasonal transmission. *Infect Immun* 2011;79(December (12)):4957–64.
- [145] Roeffen W, Lensen T, Mulder B, Teelen K, Sauerwein R, Van Druten J, et al. A comparison of transmission-blocking activity with reactivity in a *Plasmodium falciparum* 48/45-kD molecule-specific competition enzyme-linked immunosorbent assay. *Am J Trop Med Hyg* 1995;52(January (1)):60–5.
- [146] Drakeley CJ, Mulder L, Tchuinkam T, Gupta S, Sauerwein R, Targett GA. Transmission-blocking effects of sera from malaria-exposed individuals on *Plasmodium falciparum* isolates from gametocyte carriers. *Parasitology* 1998;116(May (Pt 5)):417–23.
- [147] Kocken CH, Jansen J, Kaan AM, Beckers PJ, Ponnudurai T, Kaslow DC, et al. Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of *Plasmodium falciparum*. *Mol Biochem Parasitol* 1993;61(September (1)):59–68.
- [148] Milek RL, DeVries AA, Roeffen WF, Stunnenberg H, Rottier PJ, Konings RN. *Plasmodium falciparum*: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cells. *Exp Parasitol* 1998;90(October (2)):165–74.
- [149] Milek RL, Stunnenberg HG, Konings RN. Assembly and expression of a synthetic gene encoding the antigen Pfs48/45 of the human malaria parasite *Plasmodium falciparum* in yeast. *Vaccine* 2000;18(January (14)):1402–11.
- [150] Milek RL, Roeffen WF, Kocken CH, Jansen J, Kaan AM, Eling WM, et al. Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite *Plasmodium falciparum* produced in *Escherichia coli*. *Parasite Immunol* 1998;20(August (8)):377–85.
- [151] Mamedov T, Ghosh A, Jones RM, Mett V, Farrance CE, Musiychuk K, et al. Production of non-glycosylated recombinant proteins in *Nicotiana benthamiana* plants by co-expressing bacterial PNGase F. *Plant Biotechnol J* 2012;10(September (7)):773–82.
- [152] Jones CS, Luong T, Hannon M, Tran M, Gregory JA, Shen Z, et al. Heterologous expression of the C-terminal antigenic domain of the malaria vaccine candidate Pfs48/45 in the green algae *Chlamydomonas reinhardtii*. *Appl Microbiol Biotechnol* 2012;May.
- [153] Chowdhury DR, Angov E, Kariuki T, Kumar N. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in *Escherichia coli*. *PLoS ONE* 2009;4(7):e6352.
- [154] Ouchkourou NS, Roeffen W, Kaan A, Jansen J, Luty A, Schuiffel D, et al. Correctly folded Pfs48/45 protein of *Plasmodium falciparum* elicits malaria transmission-blocking immunity in mice. *Proc Natl Acad Sci U S A* 2008;105(March (11)):4301–5.
- [155] Theisen M, Roeffen W, Singh SK, Andersen G, Amoah L, van de Vegte-Bolmer M, et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. *Vaccine* 2014;32(May (22)):2623–30.
- [156] Singh SK, Roeffen W, Andersen G, Bousema T, Christiansen M, Sauerwein R, et al. A *Plasmodium falciparum* 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies. *Vaccine* 2015;33(April (16)):1981–6.
- [157] Nikolaeva D, Draper SJ, Biswas S. Toward the development of effective transmission-blocking vaccines for malaria. *Expert Rev Vaccin* 2015;January:1–28.
- [158] Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. *PLoS ONE* 2008;3(7):e2636.
- [159] Cheru L, Wu Y, Diouf A, Moretz SE, Muratova OV, Song G, et al. The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. *Vaccine* 2010;28(June (27)):4423–9.
- [160] Kumar R, Angov E, Kumar N. Potent malaria transmission-blocking antibody responses elicited by *Plasmodium falciparum* Pfs25 expressed in *Escherichia coli* after successful protein refolding. *Infect Immun* 2014;82(April (4)):1453–9.
- [161] Tsuboi T, Takeo S, Iriko H, Jin L, Tsuchimochi M, Matsuda S, et al. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. *Infect Immun* 2008;76(April (4)):1702–8.
- [162] Farrance CE, Chichester JA, Musiychuk K, Shamol M, Rhee A, Manceva SD, et al. Antibodies to plant-produced *Plasmodium falciparum* sexual stage protein Pfs25 exhibit transmission blocking activity. *Hum Vaccin* 2011;7(January–February (Suppl.)):191–8.
- [163] Gregory JA, Li F, Tomosada LM, Cox CJ, Topol AB, Vinetz JM, et al. Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission. *PLoS ONE* 2012;7(5):e37179.
- [164] Zou L, Miles AP, Wang J, Stowers AW. Expression of malaria transmission-blocking vaccine antigen Pfs25 in *Pichia pastoris* for use in human clinical trials. *Vaccine* 2003;21(April (15)):1650–7.
- [165] Kaslow DC, Bathurst IC, Lensen T, Ponnudurai T, Barr PJ, Keister DB. *Saccharomyces cerevisiae* recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of *Plasmodium falciparum*. *Infect Immun* 1994;62(December (12)):5576–80.
- [166] Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, Miller LH, et al. Long-lasting and transmission-blocking activity of antibodies to *Plasmodium falciparum* elicited in mice by protein conjugates of Pfs25. *Proc Natl Acad Sci U S A* 2007;104(January (1)):293–8.
- [167] Kubler-Kielb J, Majadly F, Biesova Z, Mocca CP, Guo C, Nussenzweig R, et al. A bicomponent *Plasmodium falciparum* investigational vaccine composed of protein-peptide conjugates. *Proc Natl Acad Sci U S A* 2010;107(January (3)):1172–7.
- [168] Wu Y, Przywiecki C, Flanagan E, Bello-Irizarry SN, Ionescu R, Muratova O, et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. *Proc Natl Acad Sci U S A* 2006;103(November (48)):18243–8.
- [169] Shimp Jr RL, Rowe C, Reiter K, Chen B, Nguyen V, Aebig J, et al. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. *Vaccine* 2013;31(June (28)):2954–62.
- [170] Gregory JA, Topol AB, Doerner DZ, Mayfield S. Alga-produced cholera toxin-Pfs25 fusion proteins as oral vaccines. *Appl Environ Microbiol* 2013;79(July (13)):3917–25.
- [171] Ogun SA, Dumon-Seignovert L, Marchand JB, Holder AA, Hill F. The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria. *Infect Immun* 2008;76(August (8)):3817–23.

- [172] Moorthy VS, Newman RD, Okwo-Bele JM. Malaria vaccine technology roadmap. *Lancet* 2013;382(November (9906)):1700–1.
- [173] Kester KE, Gray Heppner Jr D, Morris P, Ofori-Anyinam O, Krzych U, Tornieporth N, et al. Sequential phase 1 and phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults. *Vaccine* 2014;32(November (49)):6683–91.
- [174] McCarthy JS, Marjason J, Elliott S, Fahey P, Bang G, Malkin E, et al. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide(R) ISA 720. *PLoS ONE* 2011;6(9):e24413.
- [175] Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D, et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. *Vaccine* 2000;18(May (23)):2504–11.
- [176] El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, Thompson D, et al. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. *Clin Vaccin Immunol* 2010;17(October (10)):1552–9.
- [177] Herrera S, Fernandez OL, Vera O, Cardenas W, Ramirez O, Palacios R, et al. Phase I safety and immunogenicity trial of *Plasmodium vivax* CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. *Am J Trop Med Hyg* 2011;84(February (2 Suppl.)):12–20.
- [178] Durying C. Development of pregnancy-associated malaria vaccines using the ExpreSS2 insect cell expression system. *BioProcess J* 2012;11(3):14–9.
- [179] Noe AR, Espinosa D, Li X, Coelho-Dos-Reis JG, Funakoshi R, Giardina S, et al. A full-length *Plasmodium falciparum* recombinant circumsporozoite protein expressed by *Pseudomonas fluorescens* platform as a malaria vaccine candidate. *PLoS ONE* 2014;9(9):e107764.
- [180] Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, et al. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. *PLoS ONE* 2007;2(10):e1018.
- [181] Hutchings CL, Birkett AJ, Moore AC, Hill AV. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. *Infect Immun* 2007;75(December (12)):5819–26.
- [182] Patarroyo ME, Bermudez A, Alba MP. The high immunogenicity induced by modified sporozoites' malarial peptides depends on their phi (varphi) and psi (psi) angles. *Biochem Biophys Res Commun* 2012;429(December (1–2)):81–6.
- [183] Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. *Science* 2012;337(July (6091)):183–6.
- [184] McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. *Science* 2013;342(November (6158)):592–8.
- [185] Hodgson SH, Choudhary P, Elias SC, Milne KH, Rampling TW, Biswas S, et al. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial. *Mol Ther* 2014;22(December (12)):2142–54.
- [186] Ockenhouse CF, Regules J, Tosh D, Cowden J, Kathcart A, Cummings J, et al. Ad35.CS.01 – RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-naïve adults. *PLOS ONE* 2015;10(7):e0131571.
- [187] Schmitt N, Bentebibel SE, Ueno H. Phenotype and functions of memory Tfh cells in human blood. *Trends Immunol* 2014;July.
- [188] Crotty S. T follicular helper cell differentiation, function, and roles in disease. *Immunity* 2014;41(October (4)):529–42.
- [189] Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, et al. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the *in vitro* growth inhibition assay. *Clin Vaccin Immunol* 2009;16(July (7)):963–8.
- [190] Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. *Nat Rev Immunol* 2011;11(January (1)):57–64.
- [191] Sheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ, Edwards NJ, et al. Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. *PLoS ONE* 2013;8(6):e65960.
- [192] Sheehy SH, Douglas AD, Draper SJ. Challenges of assessing the clinical efficacy of asexual blood-stage *Plasmodium falciparum* malaria vaccines. *Hum Vaccin Immunother* 2013;9(September (9)):1831–40.
- [193] Duncan CJ, Draper SJ. Controlled human blood stage malaria infection: current status and potential applications. *Am J Trop Med Hyg* 2012;86(April (4)):561–5.
- [194] Douglas AD, Edwards NJ, Duncan CJ, Thompson FM, Sheehy SH, O'Hara GA, et al. Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection. *J Infect Dis* 2013;208(May (2)):340–5.
- [195] Hodgson SH, Juma E, Salim A, Magiri C, Kimani D, Njenga D, et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to *Plasmodium falciparum* using sporozoites administered by intramuscular injection. *Front Microbiol* 2014;5:686.
- [196] Stanisic DI, Liu XQ, De SL, Batzloff MR, Forbes T, Davis CB, et al. Development of cultured *Plasmodium falciparum* blood-stage malaria cell banks for early phase *in vivo* clinical trial assessment of anti-malaria drugs and vaccines. *Malar J* 2015;14(1):143.
- [197] Teirlinck AC, Roestenberg M, van de Vegte-Bolmer M, Scholzen A, Heinrichs MJ, Siebelink-Stoter R, et al. NF135.C10: a new *Plasmodium falciparum* clone for controlled human malaria infections. *J Infect Dis* 2013;207(February (4)):656–60.
- [198] McCarthy JS, Griffin PM, Sekuloski S, Bright AT, Rockett R, Looke D, et al. Experimentally induced blood-stage *Plasmodium vivax* infection in healthy volunteers. *J Infect Dis* 2013;208(November (10)):1688–94.